Aperio Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $117M | Buy |
3,344,206
+178,382
| +6% | +$6.17M | 0.35% | 51 |
|
|
2020
Q3 | $110M | Sell |
3,165,824
-58,190
| -2% | -$1.94M | 0.37% | 50 |
|
|
2020
Q2 | $106M | Buy |
3,224,014
+136,416
| +4% | +$4.35M | 0.39% | 45 |
|
|
2020
Q1 | $92.9M | Buy |
3,087,598
+280,070
| +10% | +$8.34M | 0.41% | 45 |
|
|
2019
Q4 | $81.3M | Buy |
2,807,528
+5,938
| +0.2% | +$164K | 0.29% | 64 |
|
|
2019
Q3 | $72.4M | Buy |
2,801,590
+112,396
| +4% | +$2.84M | 0.29% | 63 |
|
|
2019
Q2 | $68.6M | Buy |
2,689,194
+363,006
| +16% | +$8.97M | 0.28% | 66 |
|
|
2019
Q1 | $60.8M | Buy |
2,326,188
+265,548
| +13% | +$6.53M | 0.26% | 73 |
|
|
2018
Q4 | $47.5M | Sell |
2,060,640
-116,364
| -5% | -$2.59M | 0.24% | 83 |
|
|
2018
Q3 | $51.3M | Buy |
2,177,004
+68,176
| +3% | +$1.66M | 0.23% | 92 |
|
|
2018
Q2 | $48.6M | Buy |
2,108,828
+120,554
| +6% | +$2.87M | 0.23% | 85 |
|
|
2018
Q1 | $49M | Buy |
1,988,274
+193,076
| +11% | +$5.07M | 0.24% | 82 |
|
|
2017
Q4 | $48.2M | Buy |
1,795,198
+192,062
| +12% | +$4.88M | 0.24% | 81 |
|
|
2017
Q3 | $38.6M | Buy |
1,603,136
+185,226
| +13% | +$4.19M | 0.22% | 99 |
|
|
2017
Q2 | $30.4M | Buy |
1,417,910
+213,068
| +18% | +$4.3M | 0.19% | 120 |
|
|
2017
Q1 | $20.7M | Sell |
1,204,842
-3,014
| -0.2% | -$52.5K | 0.14% | 171 |
|
|
2016
Q4 | $21.7M | Sell |
1,207,856
-300,570
| -20% | -$5.45M | 0.17% | 136 |
|
|
2016
Q3 | $31.4M | Sell |
1,508,426
-211,394
| -12% | -$5.24M | 0.23% | 100 |
|
|
2016
Q2 | $46.2M | Buy |
1,719,820
+101,522
| +6% | +$2.78M | 0.36% | 54 |
|
|
2016
Q1 | $43.8M | Sell |
1,618,298
-28,042
| -2% | -$751K | 0.38% | 51 |
|
|
2015
Q4 | $47.8M | Buy |
1,646,340
+120,614
| +8% | +$3.34M | 0.44% | 45 |
|
|
2015
Q3 | $41.4M | Buy |
1,525,726
+124,134
| +9% | +$3.51M | 0.42% | 42 |
|
|
2015
Q2 | $38.4M | Buy |
1,401,592
+126,066
| +10% | +$3.54M | 0.4% | 44 |
|
|
2015
Q1 | $34M | Sell |
1,275,526
-1,800
| -0.1% | -$41.4K | 0.38% | 47 |
|
|
2014
Q4 | $27M | Buy |
1,277,326
+19,502
| +2% | +$436K | 0.33% | 59 |
|
|
2014
Q3 | $29.9M | Buy |
1,257,824
+87,516
| +7% | +$2.01M | 0.4% | 43 |
|
|
2014
Q2 | $27M | Buy |
1,170,308
+58,642
| +5% | +$1.29M | 0.39% | 46 |
|
|
2014
Q1 | $25.4M | Buy |
+1,111,666
| New | +$23.7M | 0.36% | 45 |
|
|
2013
Q4 | – | Sell |
-851,530
| Closed | -$14.8M | – | 63 |
|
|
2013
Q3 | $14.4M | Buy |
851,530
+166,190
| +24% | +$2.8M | 0.28% | 64 |
|
|
2013
Q2 | $10.6M | Buy |
+685,340
| New | +$11.4M | 0.25% | 76 |
|
Other funds holding NVO
F
EHC
Aperio Group's NVO Position: Q4 2020 in Review
Aperio Group increased its Novo Nordisk (NVO) stake by 5.6% in Q4 2020, buying an estimated $6.17M and bringing the position to 3,344,206 shares worth $117M. The position accounts for 0.35% of the portfolio, ranked #51.
Aperio Group first reported a position in NVO in Q2 2013 and has held it in 30 quarters since. 702 funds tracked by Wall St. Rank hold NVO as of Q4 2020.
- Aperio Group held 3,344,206 shares of Novo Nordisk worth $117M as of Q4 2020.
- Aperio Group bought 178,382 Novo Nordisk shares in Q4 2020, an estimated $6.17M.
- Novo Nordisk made up 0.35% of Aperio Group's portfolio in Q4 2020, its #51 holding.
- Aperio Group first reported a position in Novo Nordisk in Q2 2013 and has held it in 30 quarters since.
- 702 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.